MX9706062A - FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA. - Google Patents

FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.

Info

Publication number
MX9706062A
MX9706062A MX9706062A MX9706062A MX9706062A MX 9706062 A MX9706062 A MX 9706062A MX 9706062 A MX9706062 A MX 9706062A MX 9706062 A MX9706062 A MX 9706062A MX 9706062 A MX9706062 A MX 9706062A
Authority
MX
Mexico
Prior art keywords
beta
lactam antibiotic
oral dosage
granulate
forms containing
Prior art date
Application number
MX9706062A
Other languages
English (en)
Spanish (es)
Inventor
Robertus Cornelis Van Koutrik
Gerrit Jan Sijbrands
Original Assignee
Yamanouchi Europ Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Europ Bv filed Critical Yamanouchi Europ Bv
Publication of MX9706062A publication Critical patent/MX9706062A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
MX9706062A 1995-02-08 1996-02-08 FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA. MX9706062A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200313 1995-02-08
PCT/EP1996/000547 WO1996024337A1 (en) 1995-02-08 1996-02-08 ORAL DOSAGE-FORMS CONTAINING A β-LACTAM ANTIBIOTIC

Publications (1)

Publication Number Publication Date
MX9706062A true MX9706062A (es) 1997-10-31

Family

ID=8220003

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9706062A MX9706062A (es) 1995-02-08 1996-02-08 FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.

Country Status (19)

Country Link
US (1) US5948422A (cs)
EP (1) EP0801559B1 (cs)
CN (1) CN1125636C (cs)
AT (1) ATE216576T1 (cs)
AU (1) AU4789696A (cs)
BG (1) BG63528B1 (cs)
BR (1) BR9607189A (cs)
CZ (1) CZ293718B6 (cs)
DE (1) DE69620866T2 (cs)
DK (1) DK0801559T3 (cs)
EA (2) EA000361B1 (cs)
ES (1) ES2175073T3 (cs)
HU (1) HU227938B1 (cs)
MX (1) MX9706062A (cs)
NO (1) NO319993B1 (cs)
PL (1) PL186386B1 (cs)
PT (1) PT801559E (cs)
WO (1) WO1996024337A1 (cs)
ZA (1) ZA961018B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
SK3999A3 (en) * 1996-07-16 1999-07-12 Gist Brocades Nv 'beta'-lactam granules free of organic solvents
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
US6596311B1 (en) * 1998-03-06 2003-07-22 Eurand International S.P.A. Fast disintegrating tablets
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
DE19922537A1 (de) * 1999-05-10 2000-11-16 Roland Bodmeier Darreichungsform zur Applikation in Körperöffnungen
US20040034039A1 (en) * 2000-09-22 2004-02-19 Yoshinori Nakano Solid preparations
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
KR20030094244A (ko) * 2001-02-05 2003-12-11 알.피.쉐러 테크놀러지즈 인코포레이티드 약리학적 활성제의 맛을 감소시키기 위한 방법 및 조성물
RU2190403C1 (ru) * 2001-09-27 2002-10-10 Нестерук Владимир Викторович Фармацевтическая композиция, обладающая антибактериальным действием, и способ ее получения
BR0308343A (pt) * 2002-03-12 2006-06-06 Bristol Myers Squibb Co composições farmacêuticas na forma de pó, método para preparar uma suspensão oral de uma droga, método para mascarar o sabor amargo ou outro sabor de uma droga e suspensão oral de des-quinolona
PT1555024E (pt) * 2002-10-02 2010-11-18 Meiji Seika Kaisha Composição medicinal antibacteriana com absorção oral melhorada
EP3473251B1 (en) * 2002-12-20 2023-12-13 NicoNovum AB A nicotine-cellulose combination
JP4926703B2 (ja) * 2003-07-03 2012-05-09 セルトリ・テクノロジーズ・エルエルシー セルトリ細胞および筋様細胞を含有する組成物、並びに細胞性移植における該組成物の使用
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
JP2009515993A (ja) 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CA2658951A1 (en) * 2006-07-28 2008-01-31 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof
WO2010031552A1 (en) * 2008-09-17 2010-03-25 Niconovum Ab Process for preparing snuff composition
WO2010077911A1 (en) * 2008-12-17 2010-07-08 Altheus Therapeutics, Inc. Enema formulations
WO2023204773A1 (en) * 2022-04-20 2023-10-26 Bilim Ilac Sanayii Ve Ticaret A.S. Tablet formulations for the treatment of urinary system infections and method for the preparation of such formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3344030A (en) * 1964-06-15 1967-09-26 American Home Prod Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables
DE2251249A1 (de) * 1972-10-19 1974-05-02 Hoechst Ag Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
DE68916983T2 (de) * 1988-02-25 1995-01-19 Yamanouchi Europ Bv Verfahren zur Herstellung eines pharmazeutischen Granulats.
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
AU715177B2 (en) * 1994-04-13 2000-01-20 Research Corporation Technologies, Inc. Methods of treating disease using sertoli cells and allografts or xenografts
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin

Also Published As

Publication number Publication date
HU227938B1 (en) 2012-06-28
PL321567A1 (en) 1997-12-08
HUP9801677A3 (en) 1999-05-28
NO973646D0 (no) 1997-08-07
EA003736B1 (ru) 2003-08-28
DE69620866D1 (de) 2002-05-29
PL186386B1 (pl) 2004-01-30
HUP9801677A2 (hu) 1998-11-30
ZA961018B (en) 1997-08-08
EA000361B1 (ru) 1999-06-24
DE69620866T2 (de) 2003-02-27
CZ230297A3 (en) 1997-11-12
NO973646L (no) 1997-09-11
ES2175073T3 (es) 2002-11-16
EA199700093A1 (ru) 1998-02-26
CN1173816A (zh) 1998-02-18
DK0801559T3 (da) 2002-06-17
WO1996024337A1 (en) 1996-08-15
BR9607189A (pt) 1997-11-11
EP0801559B1 (en) 2002-04-24
US5948422A (en) 1999-09-07
CN1125636C (zh) 2003-10-29
BG63528B1 (bg) 2002-04-30
EP0801559A1 (en) 1997-10-22
BG101822A (en) 1998-04-30
PT801559E (pt) 2002-09-30
EA199900205A1 (ru) 2000-06-26
AU4789696A (en) 1996-08-27
NO319993B1 (no) 2005-10-10
CZ293718B6 (cs) 2004-07-14
ATE216576T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
MX9706062A (es) FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.
HU206683B (en) Process for producing 1,5-diphenyl-pyrazolo-3-carboxylic acid derivatives and selective herbicide compositions containing them as antidotum
HUT43239A (en) Plant protective compositions comprising acryl acid derivatives as active substance and process for preparing the active substances
JO1969B1 (en) Granulation process for the preparation of rapidly dissolving and dissolving compounds containing a high amount of the drug
HUT60784A (en) Process for producing n,o-sulfated heparosanes and pharmaceutical compositions comprising such compounds
HUT49366A (en) Process for producing 2',3'-dideoxy-2',2'-difluoronucleosides and pharmaceutical compositions comprising same
DE69616072D1 (de) Stabile feste formulierung eines enalaprilsalzes und verfahren zu deren herstellung
HUP9601358A2 (en) Fluoro-phenyl-substituted alkenyl-carboxylic-guanidines, process for producing them, their use as medicines or diagnostica, and pharmaceutical compositions containing them
HU9601321D0 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, their use as pharmaceutical compositions or diagnostica, and pharmaceutical compositions containing them
IL83978A (en) Process and compositions containing dihalopyridine derivatives for protecting plants against diseases,certain such novel derivatives and their preparation
HUT55004A (en) Process for producing 1,3-disubstituted 5-aryl-carbamoyl-4(6)-oxo-6(4)-oxido-pyrimidine-betaine derivatives and anthelmintic compositions containing them as active components
HUP0103347A3 (en) Aminoalcohol derivatives and their use as betha 3 adrenergic agonists, process for their preparation and pharmaceutical compositions containing them
ZA901543B (en) Benzoxazolinone derivatives,process for preparing them and pharmaceutical compositions containing them
HUP9801439A3 (en) Use of beta-d-galactopyranosyl-d-xyloses for the preparation of compositions and solutions intended to the evaluation of intestinal lactase, and production process of the said compds.
PL331588A1 (en) Granulated products containing a water-soluble compound and cellulose
HUT37423A (en) Process for preparing 1,3-dioxolanyl derivatives and pharmaceutical compositions containing thereof
HUT35156A (en) Plant protecting compositions containing 3-cycloalkyl-1-/1,3-dioxan-5-y1/-2-/1,2,4-truazol-1-y1/-propan-1-one and -propan-1-01 derivatives as active agents and process for producing the active agents
DE69915785D1 (de) Pulverförmige Dextrose und Verfahren zur Herstellung derselben
HU913540D0 (en) Process for the protection of plant cultivation by using triazolyl- or imidazolyl-methyl-allyl-alcoholes, and the new compounds used in the process
HUP0002767A3 (en) Carbohydrate-based enzyme granulates
HUT37769A (en) Herbicide compositions containing thiazoly-urea derivative as active agent, and process for producing thiazolyl-urea derivatives
HUT52071A (en) Process for producing 1-amino-alkyl-3-oxy-4-aryl-1,3,4,5-tetrahydro-2h-1,3-benzodiazepin-2-one derivatives and pharmaceutical compositions containing them as active components
HUT48241A (en) Herbicide compositions containing halogenated cyclopropan derivatives as active components and process for producing the active components
TW334424B (en) L-arginine aldehyde derivatives process for preparing them and pharmaceutical composition
EP0470516A3 (en) Process for producing 3,5-di(alpha-methylbenzyl)salicylic acid derivative, and use of polyvalent-metal-modified product thereof as color developer